bpc 157 on angiogenesis central nervous system BPC157 drives through FBXO22-dependent stabilization of BACH1 | Cell Communication and Signaling Therapeutic potential of pro-angiogenic BPC157

Together with Src and integrins, a substantial body of work has been completed on the Rho/ROCK pathway to describe mechanotransduction in a wide variety of cells in both physiological and pathological conditions (222)

While researchers note that the LD50 (lethal dose) for GHK-Cu in murine models equates to an impossibly massive single dose of roughly 23,000mg for a 70kg human adultrendering acute lethal toxicity highly improbable at the standard aesthetic therapeutic doses of 5-50mgthe long-term cumulative effects of daily copper peptide injections remain entirely unmapped in human populations

Rotating injection sites prevents these reactions from accumulating or worsening

BPC-157 addresses muscular and connective tissue repair

MRD- rate in the intent-to-treat population was 29.6% in IKEMA and 17.6% in CANDOR at 12 months

Indications for use - polyneuropathy of various origins - neuritis and neuralgia - radiculoneuritis due to degenerative diseases of the spine (cervical syndrome, hand and forearm cider, lumbar syndrome) - sciatica - trigeminal neuralgia, intercostal neuralgia Method of administration and dosage The drug is injected only intramuscularly (in the upper outer quadrant of the gluteus maximus muscle)